Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Terminated · Phase 1 · NCT02400242
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $3,200
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 85
About the trial
- Sponsor
- Celgene
- Tested
- ACY-241 (drug), Pomalidomide (drug), Dexamethasone (drug)
- Dates
- Started 2015-05-07; completion 2024-06-03
- Results posted
- Not yet
This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomide and low-dose dexamethasone in eligible patients with relapsed or relapsed-and-refractory multiple myeloma (MM).
From ClinicalTrials.gov, last updated 2024-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $3,200 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Arizona, Div of Sponsored Programs $3,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.